Current Report Filing (8-k)
September 18 2017 - 12:04PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
______________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event
reported): September 18, 2017
____________________________
ChineseInvestors.com, Inc.
(Exact name of registrant as specified
in its charter)
____________________________
Indiana
|
|
000-54207
|
|
35-2089868
|
(State of Organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification Number)
|
227 W. Valley Blvd. #208A, San Gabriel, CA
|
|
91776
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(626) 589-2468
(Registrant’s telephone number, including
area code)
Check appropriate box below if the Form 8-K filing is intended
to simultaneously satisfying the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Item 8.01 Other Events
ChineseInvestors.com,, Inc. announces
that CBD Biotechnology Co. Ltd., its wholly owned foreign enterprise in China, has completed the filing process with the China
Food & Drug Administration and may commence selling its new line of hemp oil infused cosmetics in October 2017.
Item 9.01 Exhibits
Copy of press release
that the Company issued on September 18, 2017 in which the Company reports on the completion of the filing process with the China
Food & Drug Administration permitting the Company’s wholly owned foreign enterprise, CBD Biotechnology Co. Ltd. to commence
marketing its
hemp-infused cosmetics
.
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly
authorized.
Date: September 18, 2017
ChineseInvestors.com, Inc.
By:
/s/ Wei Wang
Name: Wei Wang
Title: Chief Executive Officer